Company intelligence / Profile preview

Pephexia Therapeutics

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Pephexia Therapeutics develops novel peptide-based drugs targeting cachexia and related muscle-wasting conditions. Their lead candidate PEP‑366 targets cancer cachexia and has received significant grant funding to support progression toward clinical trials. The company has presented promising preclinical data at major scientific conferences but has not yet reported human clinical results as of mid‑2025.

Therapeutic areas: Metabolic DisordersPulmonologyOncologyNephrologyImmunologyCardiovascular
Modalities: PeptidesPeptide-based pharmacotherapies
Industry: Biotech

Drug pipeline

2 assets

PEP-064

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Danish Innovation Fund (via Grand Solution grant)

Beyond the preview

Go deeper on Pephexia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pephexia Therapeutics.

Explore the full profile